Anterior segment changes following intravitreal bevacizumab injection for treatment of neovascular glaucoma
Canut, Maria Isabel (Glaucoma Section)
Alvarez, A. (Centre d'Oftalmologia Barraquer (Barcelona, Catalunya))
Nadal Reus, Jeroni (Centre d'Oftalmologia Barraquer (Barcelona, Catalunya))
Abreu, Rodrigo (Hospital Universitario Nuestra Señora de Candelaria (Santa Cruz de Tenerife))
Abreu, José Augusto (Glaucoma Section, University Hospital of the Canary Islands, Tenerife, Spain)
Pulido, Josè S. (Retina and Vitreous Unit, Ophthalmology Department, Mayo Clinic, Rochester, MN, USA)
Universitat Autònoma de Barcelona

Date:	2011
Abstract:	The purpose of this study was to describe anterior segment changes in a prospective, interventional, noncomparative case series of patients with neovascular glaucoma secondary to proliferative diabetic retinopathy treated with intravitreal bevacizumab. Five consecutive patients with neovascular glaucoma and a refractory, symptomatic elevation of intraocular pressure and pronounced anterior segment congestion received intravitreal bevacizumab 1. 25 mg/0. 05 mL. Follow-up examinations were performed at 4-16 weeks by the same specialists, with testing performed at hour 48, week 1, and months 1, 3, and 6 after intravitreal bevacizumab. We observed a significant difference (P = 0. 021) between initial and mean neovascularization at three months in all the quadrants. At three months, median intraocular pressure was 19 ± 5. 38 (range 12-26) mmHg. In three of the five cases, diode laser cyclophotocoagulation was required, and in one case a trabeculectomy was performed. One patient showed complete synechial angle closure 48 hours after treatment which required cyclodestructive procedures to normalize intraocular pressure. Intravitreal bevacizumab achieves complete regression of neovascularization in neovascular glaucoma secondary to proliferative diabetic retinopathy, and this regression is stable when associated with treatment of the underlying disease and should be investigated more thoroughly as an adjunct in the management of neovascular glaucoma.
Rights:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, sempre que no sigui amb finalitats comercials, i sempre que es reconegui l'autoria de l'obra original.
Language:	Anglès
Document:	Article ; recerca ; Versió publicada
Published in:	Clinical Ophthalmology (Auckland, N.Z.), Vol. 5 (may 2011) , p. 715-719, ISSN 1177-5483

DOI: 10.2147/OPTH.S17350
PMID: 21629579

5 p, 1.6 MB

The record appears in these collections:
Articles > Research articles
Articles > Published articles